Girvan D P, deVeber L L, Inwood M J, Clegg E A
Children's Hospital of Western Ontario, Canada.
J Pediatr Surg. 1994 Sep;29(9):1220-3. doi: 10.1016/0022-3468(94)90806-0.
Central venous access devices have become important tools in the management of pediatric patients with malnutrition, malignancy, and infections requiring long-term antibiotic treatment. Hemophilia presents a lifetime challenge for venous access and at times can be an urgent or life-threatening situation. Since 1986, the authors have implanted 11 subcutaneous infusion ports in nine patients with hemophilia. The systems have remained in place for up to 7 years, without major complications or problems. Two catheters were replaced, after 4 and 6 years, because of skin erosion and blockage, respectively. One catheter was removed after 7 years because of blockage following local trauma and was not replaced. A recent survey through the Canadian Hemophilia Centre Directors Group obtained a further 45 subcutaneous infusion ports in other centers across Canada. The benefits of this system are overwhelming enthusiasm by the parents and children and no major complications. Some of the patients are now HIV-positive and are able to use their system for ongoing drug therapy.
中心静脉通路装置已成为治疗患有营养不良、恶性肿瘤以及需要长期抗生素治疗的感染的儿科患者的重要工具。血友病给静脉通路带来了终身挑战,有时可能是紧急或危及生命的情况。自1986年以来,作者已为9例血友病患者植入了11个皮下输注端口。这些系统已使用长达7年,无重大并发症或问题。两根导管分别在4年和6年后因皮肤侵蚀和堵塞而更换。一根导管在7年后因局部创伤后堵塞而取出,未予更换。最近通过加拿大血友病中心主任小组进行的一项调查在加拿大其他中心又获得了45个皮下输注端口。该系统的优点是患儿及其家长对此极为认可,且无重大并发症。一些患者现已感染艾滋病毒,仍能够使用该系统进行持续药物治疗。